First-line Chemotherapy for Extensive-disease Small Cell Lung Cancer:A Network Meta-analysis
10.3779/j.issn.1009-3419.2016.04.02
- VernacularTitle:一线化疗方案治疗广泛期小细胞肺癌的网状meta分析
- Author:
CHEN YUJIE
1
;
CHEN LINGXIAO
;
ZHONG DIANSHENG
;
WANG JING
;
PENG LINA
;
FENG XIN
Author Information
1. 天津医科大学总医院肿瘤科
- Keywords:
Meta-analysis;
Small cell lung cancer;
First-line chemotherapy
- From:
Chinese Journal of Lung Cancer
2016;19(4):184-191
- CountryChina
- Language:Chinese
-
Abstract:
Background and objective Regimens that combine irinotecan or etoposide with cisplatin or carbo-platin have been recommended as ifrst-line regimen for extensive-disease small cell lung cancer (ED-SCLC). In our network meta-analysis, we synthesized the direct and indirect lines of evidence to rank the short-term effcacies of these recommended chemotherapy regimens. Methods We searched databases, including EMBASE, PubMed, CENTARL and clinicaltrial.gov, for relevant randomized controlled trials (RCTs) that compared the effcacies of these treatments. A risk of bias tool was used to evaluate the quality of the included studies, whereas Stata 13.1 was used for statistical synthesis. Results Our study included 10 RCTs that involved 2,378 patients. Compared with that of the regimen that combined etoposide and carboplatin, the complete remission rate was signiifcantly higher in the group treated with irinotecan combined with carboplatin. hTe effcacy of the regi-men that combined irinotecan with carboplatin was signiifcantly superior over that of the combination of etoposide and cis-platin. Conclusion Our data presented here suggest that the effect of Irinotecan combination with Carboplatin is remarkably superior.
